Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Size: px
Start display at page:

Download "Key Findings. Use this report to... The Autoimmune Market Outlook to 2013"

Transcription

1 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in Immunosuppressant drugs dominate the automimnune market, with four products from this class accounting for 40.3% of total market sales. The highest selling immunosuppressant drug was J&J/Schering-Plough s Remicade, with 42.1% of total sales in this class. Pfizer s Celebrex dominated the COX-II market with a share of 81.3% in. Celebrex maintained blockbuster status despite the earlier withdrawals of major blockbuster COX-II inhibitors such as Vioxx and Bextra. Figure 5.6: Competitive dynamics of leading players in the autoimmune market, Roche ($1.7bn) and Astellas ($1.6bn), two of the leading companies in the global autoimmune market, also registered a strong year-on-year sales growth of 13.2% and 19.3% in, driven mainly by the strong sales growth of CellCept and Prograf, respectively... Roche s Actemra is expected to be launched in the US during Q1 2010, in view of the FDA s request for additional data and Roche s risk mitigation strategy. Actemra is forecast to generate sales of $680m in Amgen is the global autoimmune market leader, having accrued a market share of 11.2% ($3.6bn) in. This was driven almost entirely by Enbrel ($3.5bn) which had a sales increase of 12.2%. Novartis' developmental MS drug fingolimod (FTY-720) is one of the strongest competitors to Biogen Idec's MS franchise due to its potency and convenience of once daily oral dosing. Use this report to... Assess patient potential, treatment trends and sales patterns of major autoimmune indications over the period , with this report s coverage of osteoarthritis, rheumatoid arthritis, crohn s disease, systemic lupus erythematosus, ulcerative colitis and multiple sclerosis markets across Japan, France, Germany, Italy, Spain, the UK and the US. Discover the market dynamics of the autoimmune area and understand the impact of recent events by assessing key market trends, growth drivers and the latest issues affecting product development. Compare the market performance and strategic positioning of major pharma companies autoimmune portfolios with this report s evaluation of the franchises and market shares of Amgen, Abbott, J&J, Pfizer, Novartis, Wyeth, Roche and Astellas. Evaluate the autoimmune pipeline compounds of leading companies with this report s detailed analysis of clinically differentiated pipeline products by indication, and sales forecasts for key R&D pipeline products to 2013.

2 Explore issues including... Reduced commercial opportunity for Coxibs. The commercial opportunity for the COX-II inhibitor class has been substantially reduced due to cardiovascular safety concerns. The US withdrawals of Vioxx and Bextra, in addition to the non-approvals of Arcoxia and Prexige, are likely to restrict the growth prospects of this class in the near future. Impact of high value biologic treatments. Orencia, for use in DMARD failures, has yet to significantly affect the growth of existing agents. BMS s Orencia and Roche s Actemra target rheumatoid arthritis patients refractory to anti-tnfs, a population estimated to be between 20-40% of moderate/severe RA patients. Figure 3.27: Leading coxib brands in the global autoimmune Sales of the leading COX-2 inhibitors accounted for 99.1% of the global COX-2 market in, with a modest growth of 14.0% in sales over Sales of Pfizer s Celebrex ($2.3bn) dominated the COX-2 market, Cost of MS treatments. Research has shown that with an 81.3% share in... the cost of being diagnosed with MS in the UK is nearly 17,000 per person. The research also found that among 2,000 people surveyed from across the UK, half stated that they had to leave work due to MS, which increased the potential cost to over 25,000 per person when lost employment productivity is added. Importance of arthritis disease. Although several novel artrhitis treatments have been launched in recent years, it is possible for many patients to acheive effective disease control from the better use of existing medications. Discover... What will be the major growth indications in the autoimmune market over? Which products will be affected by generic competitors over the period? Which companies were the winners and losers in this market in? Which pipeline products will be the growth drivers of the future? How have major launches from companies such as Amgen, Roche, Abbott and J&J performed? Which indications have the highest levels of market potential over the period? Which companies will become key players in the autoimmune market over? What will be the competitive landscape in osteoarthritis, rheumatoid arthritis, crohn s disease, lupus, ulcerative colitis and multiple sclerosis in 2013?

3 Sample Information Chapter 5: Competitive landscape Sales focus by drug class Novartis markets a broad range of products across a range of therapy areas and has very comprehensive coverage of drug classes when compared to other pharmaceutical companies featured in this report. The majority of Novartis sales are derived from products falling under the immunosuppressant class of drugs with the key drug being Sandimmun (cyclosporine), which was responsible for $831m sales in. Voltaren, an NSAID accrued $1.1bn in, making it the company s top selling drug in. Voltaren is marketed Figure 5.11: Novartis autoimmune sales by in different formulations ranging from oral to topical, and thus sales accrued by Voltaren contribute towards products falling under the plain NSAIDs as well as topical anti-rheumatic agents. Business Insights Marketed product portfolio Novartis autoimmune franchise registered a growth rate of 11.7% in , representing sales of $2.6bn in. Voltaren, the company s top selling product has witnessed a strong y-o-y sales growth of 9.7% or $1.1bn in. Marketed as an oral tablet as well as a topical formulation, the oral formulation of Voltaren had witnessed a stronger sales performance in 2006, accounting for 58.2% Table 5.57: Novartis autoimmune product of total product sales. Major growth drivers Novartis autoimmune portfolio include Myfortic, which registered a strong y-o-y sales growth of 63.3%, garnering sales of $149m in. Myfortic is indicated for the reduction of organ rejection during renal transplants. The drug has strong clinical efficacy and tolerability profiles, translating into strong market performance since its launch in Business Insights Certican, a novel proliferation signal inhibitor with immunosuppressive and anti-proliferative properties is indicated for the treatment of organ rejection in transplantation, garnered sales of $50m in, representing y-o-y sales growth of 85.5%. Prexige, a COX-2 inhibitor, registered the strongest growth rate of 120.6% among all products featured in Novartis autoimmune franchise during the period. (Continued...) -181-

4 Table of Contents CHAPTER 1: SCOPE AND METHODOLOGY Scope Methodology CHAPTER 2: EPIDEMIOLOGY OF AUTOIMMUNE DISEASES Osteoarthritis Rheumatoid arthritis Crohn s disease Systemic lupus erythematosus Ulcerative colitis Multiple sclerosis CHAPTER 3: GLOBAL MARKET ANALYSIS Summary Market analysis by country Trends in generics usage and licensing Market analysis by drug class Leading brands dynamics Key events in the autoimmune market - Enbrel growth slowing as it faces stiff competition from Humira - RoActemra receives positive opinion in Europe for the treatment of RA - NICE admits previous guidance around sequential use of anti-tnf therapies in RA is unfair - Study shows prohibitive cost of MS treatment - Mayo Clinic collaborates to advance Crohn's treatment - Arthritis research shows better disease is more important than the use of drugs - CellCept s off-label use in lupus continues to increase Immunosuppressants immunosuppressants - Leading brands of immunosuppressants - Clinical developments - Immunosuppressants sales forecasts to 2013 Specific anti-rheumatic agents specific anti-rheumatic agents - Leading brands of specific antirheumatic agents - Specific anti-rheumatic agents sales forecasts to 2013 Non-steroidal plain nonsteroidal plain - Leading brands of nonsteroidal plain - Non-steroidal plain antirheumatics sales forecasts to 2013 Topical topical - Leading brands of topical - Topical anti-rheumatic sales forecasts to 2013 Coxibs coxibs - Leading brands of coxibs - Coxibs sales forecasts to 2013 Non-steroidal (combinational) non- steroidal (combinational) - Leading brands of non-steroidal (combinational) - Non-steroidal (combinational) sales forecasts to 2013 Anti-rheumatic corticosteroids antirheumatic corticosteroids - Leading brands of anti-rheumatic corticosteroids - Anti-rheumatic corticosteroids sales forecasts to 2013 Total autoimmune sales forecasts to 2013 CHAPTER 4: PIPELINE ANALYSIS Key trends in R&D - Biologics - Combination drugs - Aggressive medical therapy becoming the standard of care - TNF inhibitors has a strong presence in autoimmune market - Efforts to develop fully human monoclonal antibodies

5 Table of Contents The autoimmune pipeline Leading drugs in development Profiles of key pipeline products - Phase III compounds - Licofelone (ML3000) Merckle GmbH - Ocrelizumab (R-1594) Genentech, Biogen IDEC, Chugai and Roche - LymphoStat-B (belimumab) Human Genome Sciences (HGS) and GSK - Ofatumumab (HuMax-CD20) Genmab and GSK - Fingolimod (FTY-720) Novartis/Mitsubishi Tanabe Pharma - Fampridine-SR Acorda - Campath (alemtuzumab) Genzyme and Bayer Schering Pharma - Recently approved/marketed drugs - Cimzia (certolizumab pegol) UCB - Golimumab (CNTO-148) Centocor/Schering-Plough - Actemra (tocilizumab) Roche/Chugai - Tysabri (natalizumab) Elan/Biogen Idec - Mesavance (mesalamine) Shire Pipeline forecasts - Factors affecting forecasts - Autoimmune pipeline forecast CHAPTER 5: COMPETITIVE LANDSCAPE - Sales performance of leading players Detailed analysis of leading autoimmune players Amgen Abbott Johnson and Johnson Pfizer Novartis Wyeth - Wyeth and Pfizer Roche Astellas LIST OF FIGURES Worldwide autoimmune market share by geography, Sales of types of autoimmune brands, Prevailing treatment approach for arthritis (OA and RA) The autoimmune pipeline by indication and stage of development, Leading recently launched products and late-stage R&D in the autoimmune disorders market, 2008 Competitive dynamics of the leading players in the global autoimmune market, Amgen s autoimmune sales by Abbott s autoimmune sales by J&J s autoimmune sales by drug class, Pfizer s autoimmune sales by Novartis autoimmune sales by Wyeth s autoimmune sales by Roche s autoimmune sales by Astellas autoimmune sales by LIST OF TABLES Estimated prevalence of autoimmune diseases across seven major markets, Estimated prevalence of OA

6 Table of Contents Forecast epidemiology of OA Estimated prevalence of RA Forecast epidemiology of RA Estimated prevalence of CD Forecast epidemiology of CD Estimated prevalence of lupus Forecast epidemiology of lupus Estimated prevalence of UC Forecast epidemiology of UC Estimated prevalence of MS Forecast epidemiology of MS Worldwide autoimmune sales by countries, Breakdown of the global autoimmune market by drug class, Leading brands in the global autoimmune market, Leading immunosuppressant Remicade launch status in major markets Immunosuppressants sales forecast, Leading specific anti-rheumatic Enbrel launch status in major markets Specific anti-rheumatic agents sales forecast, Leading non-steroidal plain antirheumatic brands in the global autoimmune Non-steroidal plain antirheumatics sales forecast, Leading topical anti-rheumatic Topical anti-rheumatic sales forecast, Leading coxib brands in the global autoimmune market, Coxibs sales forecast, Leading non-steroidal (combinational) anti-rheumatic Non-steroidal (combinational) sales forecast, Leading anti-rheumatic corticosteroid brands in the global autoimmune market, Anti-rheumatic corticosteroids sales forecast, Therapeutic sales forecasts by drug class, An overview of Licofelone An overview of Ocrelizumab An overview of LymphoStat-B An overview of Ofatumumab An overview of FTY-720 An overview of Fampridine-SR Fampridine-SR Phase III data An overview of Campath An overview of Cimzia An overview of Golimumab An overview of Actemra An overview of Tysabri An overview of Mesavance Autoimmune pipeline sales forecasts, Leading players in the global autoimmune market, ($m) Amgen s autoimmune product Amgen s autoimmune R&D Abbott s autoimmune product Abbott s autoimmune R&D J&J s autoimmune product J&J s autoimmune R&D product pipeline, 2008 Pfizer s autoimmune product Pfizer s autoimmune R&D product pipeline, 2008 Novartis autoimmune product Novartis autoimmune R&D Wyeth s autoimmune product Wyeth s autoimmune R&D Roche s autoimmune product Roche s autoimmune R&D Astellas s autoimmune product Astellas s autoimmune R&D

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies Brochure More information from http://www.researchandmarkets.com/reports/1504775/ Commercial Insight: Disease Modification in Rheumatoid Arthritis - Market awaits game changing therapies and strategies

More information

Company Presentation June 2011 Biotest AG 0

Company Presentation June 2011 Biotest AG 0 Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and

More information

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,

More information

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013 Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure

More information

Global Inflammatory Bowel Disease Market

Global Inflammatory Bowel Disease Market Brochure More information from http://www.researchandmarkets.com/reports/3175853/ Global Inflammatory Bowel Disease Market 2015-2019 Description: About Inflammatory Bowel Disease Inflammatory bowel disease

More information

Multiple Sclerosis Drug Discoveries - What the Future Holds

Multiple Sclerosis Drug Discoveries - What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/1408035/ Multiple Sclerosis Drug Discoveries - What the Future Holds Description: The recent approval in the US of Novartis' orally

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Crohn s Disease: Key Metrics in the Seven Major Pharmaceutical

More information

Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018)

Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) Brochure More information from http://www.researchandmarkets.com/reports/2693611/ Global Rheumatoid Arthritis Market: Trends and Opportunities (2013-2018) Description: The report titled 'Global Rheumatoid

More information

Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module

Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module Brochure More information from http://www.researchandmarkets.com/reports/2583544/ Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module Description: What the future holds: Over the next few years,

More information

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

Bolus Injectors Market

Bolus Injectors Market Sample Pages Bolus Injectors Market 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2013 Roots Analysis Private Ltd. All rights reserved. No

More information

H E A L T H C A R E. Market trends, leading players and forecasts. Report Price Publication date. 1995/ 2880/$3835 June 2009

H E A L T H C A R E. Market trends, leading players and forecasts. Report Price Publication date. 1995/ 2880/$3835 June 2009 F o r a c l e a r e r m a r k e t p e r s p e c t i v e The US Pharmaceutical Market Outlook to 2014 Market trends, leading players and forecasts Report Price Publication date 1995/ 2880/$3835 June 2009

More information

REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Humira (adalimumab) in the 10MM (US,

More information

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician

More information

REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Simponi (golimumab) in the 10MM (US,

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report

Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1382330/ Anti-CD20 Monoclonal Antibodies - Global Strategic Business Report Description: This report analyzes the Global market

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must

More information

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019 Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive

More information

SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO EVENT-DRIVEN UPDATE

SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO EVENT-DRIVEN UPDATE REFERENCE CODE GDHC009EPIDR PUBLICATION DATE FEBRUARY 2015 SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 - Executive Summary Table below presents the

More information

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

MRC Technology Centre for Therapeutics Discovery

MRC Technology Centre for Therapeutics Discovery MRC Technology Centre for Therapeutics Discovery fast-tracking discovery and development of novel drugs from academia Dr Duncan Young Business Development Manager UbiFrance Symposium, October 2012 established

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Europe Rheumatoid Arthritis Market Highlights - 2015

Europe Rheumatoid Arthritis Market Highlights - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3447138/ Europe Rheumatoid Arthritis Market Highlights - 2015 Description: The latest research, 'Europe Rheumatoid Arthritis Market

More information

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18)

Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Global Multiple Sclerosis Market: Trends and Opportunities (2013-18) Scope of the Report The report titled Global Multiple Sclerosis Market: Trends & Opportunities (2013-18) provides an insight into the

More information

ULCERATIVE COLITIS - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO EVENT-DRIVEN UPDATE

ULCERATIVE COLITIS - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO EVENT-DRIVEN UPDATE REFERENCE CODE GDHC005EPIDR PUBLICATION DATE SEPTEMBER 2014 ULCERATIVE COLITIS - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 - Executive Summary The table below presents the key metrics for ulcerative

More information

DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS

DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS DRUGS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS: GLOBAL MARKETS PHM159A March 2014 Sanjukta Bhattacharyya Project Analyst ISBN: 1-56965-754-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

As featured in. Orphan disease specialists find home with Big Pharma.

As featured in. Orphan disease specialists find home with Big Pharma. Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT,

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT, CHAPTER ONE: INTRODUCTION... 1 REASONS FOR DOING THE STUDY... 1 STUDY GOALS AND OBJECTIVES... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 2 METHODOLOGIES AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS...

More information

SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS - GERMANY DRUG FORECAST AND MARKET ANALYSIS TO 2022

SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS - GERMANY DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC162CFR PUBLICATION DATE OCTOBER 2013 SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS Executive Summary Sales for SLE and LN in Germany, 2012 2022 GlobalData estimates 2012 Systemic Lupus Erythematosus

More information

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013 Multiple Sclerosis Global Drug Forecast and Market Analysis to 2022 Event-Driven Update GDHC34PIDR / Published April 2013 Executive Summary The table below presents the key metrics for multiple sclerosis

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Let s talk about Arthritis

Let s talk about Arthritis Let s talk about Arthritis Osteoarthritis Rheumatoid Arthritis Kam Shojania, MD, FRCPC Clinical Professor and Head, St. Paul s, UBC and VGH Divisions of Rheumatology Slides with thanks to: Cheryl Koehn

More information

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion

Rheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment

More information

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple

More information

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/2989104/ Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Description: Bosatria (Mepolizumab) (Asthma) - Forecast

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.

More information

Core therapeutic areas

Core therapeutic areas Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014

More information

REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Humira in the 10MM Ulcerative Colitis (UC)

More information

Measure #176: Rheumatoid Arthritis (RA): Tuberculosis Screening National Quality Strategy Domain: Effective Clinical Care

Measure #176: Rheumatoid Arthritis (RA): Tuberculosis Screening National Quality Strategy Domain: Effective Clinical Care Measure #176: Rheumatoid Arthritis (RA): Tuberculosis Screening National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:

More information

UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium) Press Release

UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium) Press Release UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium) Press Release Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis New data presented at EULAR confirms efficacy with either every

More information

Original Policy Date

Original Policy Date MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

****SAMPLE ***The Global Self-Monitoring Blood Glucose Market - Data, Analysis and Forecast to 2025

****SAMPLE ***The Global Self-Monitoring Blood Glucose Market - Data, Analysis and Forecast to 2025 ****SAMPLE ***The Global Self-Monitoring Blood Glucose Market - Data, Analysis and Forecast to 2025 Pharmaceutical, commercial and strategic developments in the Global Self-Monitoring Blood Glucose Market

More information

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022

Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2152222/ Xarelto (Atrial Fibrillation) - Analysis and Forecasts to 2022 Description: Xarelto (Atrial Fibrillation) Analysis and

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

UPDATED INVESTOR PRESENTATION June 2015

UPDATED INVESTOR PRESENTATION June 2015 UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans

More information

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022. Multiple Brochure More information from http://www.researchandmarkets.com/reports/2541548/ PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Description: PharmaPoint: Multiple

More information

CHAPTER SIX: SMALL MOLECULE MS DRUGS... 37

CHAPTER SIX: SMALL MOLECULE MS DRUGS... 37 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...

More information

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Brochure More information from http://www.researchandmarkets.com/reports/2075322/ Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Description: Insulin Degludec (Type 2 Diabetes) Analysis

More information

REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014

REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014 REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014 GOUT Executive Summary Gout: Key Metrics in the Six Major Pharmaceutical Markets, 2013 2018 2013 Epidemiology Gout, diagnosed prevalent population

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

REFERENCE CODE GDHC66PIDR PUBLICATION DATE NOVEM BER 2013 ATOPIC DERMATITIS GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC66PIDR PUBLICATION DATE NOVEM BER 2013 ATOPIC DERMATITIS GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC66PIDR PUBLICATION DATE NOVEM BER 2013 ATOPIC DERMATITIS Executive Summary Atopic Dermatitis: Key Metrics in the Major Pharmaceutical Markets 2012 Epidemiology Diagnosed Total Lifetime

More information

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Biologic Response Modifiers

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Biologic Response Modifiers AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Biologic Response Modifiers Drugs covered by this policy: Xeljanz, Orencia, Tysabri, Stelara, Cosentyx, Entyvio Authorization guidelines:

More information

REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN (POSTMENOPAUSAL VAGINAL ATROPHY) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC269DFR PUBLICATION DATE JULY 2013 PREMARIN Executive Summary Premarin (conjugated estrogen cream): Key Metrics in the Seven Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

Rheumatoid Arthritis Information

Rheumatoid Arthritis Information Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative

More information

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070277/ Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of

More information

Industry Analysis Competitor Analysis

Industry Analysis Competitor Analysis Course: Foundations of Business Strategy https://www.coursera.org/course/strategy101 To: Karl-Ludwig Kley, CEO - Merck KGaA From: Ju Yang Re: Merck KGaA Competitive Position Analysis in the Pharmaceuticals

More information

Strategic Market Analysis for Early Stage Oncology Companies

Strategic Market Analysis for Early Stage Oncology Companies Strategic Market Analysis for Early Stage Oncology Companies Carolyn Siegal Principal, Siegal Consulting carolyn@siegalconsulting.com 626-798-8700 Presentation Outline Services overview Analysis simplifies

More information

Building Bridges to Long-Term Growth

Building Bridges to Long-Term Growth N o 7 Building Bridges to Long-Term Growth Tanabe is working to realize its corporate philosophy of contributing to people over the world desiring to live healthy and securely through pharmaceuticals and

More information

Rheumatoid Arthritis an Update. Philip L. Cohen, M.D. Lewis Katz School of Medicine Temple University

Rheumatoid Arthritis an Update. Philip L. Cohen, M.D. Lewis Katz School of Medicine Temple University Rheumatoid Arthritis an Update Philip L. Cohen, M.D. Lewis Katz School of Medicine Temple University Disclosure Research Support from Janssen Pharmaceutials, LLC Learning Objectives Review changing clinical

More information

(THE CHANGING LANDSCAPE)

(THE CHANGING LANDSCAPE) Updating the therapeutic strategy in RA What is effective, what is changing in daily practice regarding the use of DMARDs and biological agents in the Balkan countries The Greek experience (THE CHANGING

More information

REFERENCE CODE GDHC030POA PUBLICAT ION DATE SEPTEMBER 2014

REFERENCE CODE GDHC030POA PUBLICAT ION DATE SEPTEMBER 2014 REFERENCE CODE GDHC030POA PUBLICAT ION DATE SEPTEMBER 2014 ALLERGIC CONJUNCTIVITIS Executive Summary Allergic Conjunctivitis: Key Metrics in the Six Major Pharmaceutical Markets, 2013 2018 2013 Epidemiology

More information

Brinavess (Atrial Fibrillation) - Analysis and Forecasts to 2022

Brinavess (Atrial Fibrillation) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2152220/ Brinavess (Atrial Fibrillation) - Analysis and Forecasts to 2022 Description: Brinavess (Atrial Fibrillation) Analysis

More information

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland

Medical School for Actuaries. June 12, 2013. Baltimore, Maryland Medical School for Actuaries June 12, 2013 Baltimore, Maryland Developments in the Treatment of Conditions Treated with Specialty Mediations (Cancer, MS, RA, Hemophilia) Mark S. Matusik, PharmD Developments

More information

AETNA BETTER HEALTH Prior Authorization guideline for Humira (adalimumab) and Enbrel (entanercept)

AETNA BETTER HEALTH Prior Authorization guideline for Humira (adalimumab) and Enbrel (entanercept) AETNA BETTER HEALTH Prior Authorization guideline for Humira (adalimumab) and Enbrel (entanercept) Requests for non-preferred anti-tnf s require trial and failure of TWO formulary anti-tnf s (when applicable)

More information

RE: Step Therapy Policy

RE: Step Therapy Policy December 14, 2015 Jim Carlson, PharmD Vice President, Pharmacy and Clinical Services OmedaRx 100 Southwest Market Street Portland, OR 97207 RE: Step Therapy Policy Dear Mr. Carlson: The National Infusion

More information

Cytokine and CAM Antagonists

Cytokine and CAM Antagonists Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs

More information

Orphan Drug Strategies

Orphan Drug Strategies Brochure More information from http://www.researchandmarkets.com/reports/1088155/ Orphan Drug Strategies Description: With the pharmaceutical industry reducing its focus on the primary care blockbuster

More information

Active Clinical Trials

Active Clinical Trials Active Clinical Trials 1. Genentech Efalizumab Protocol No. ACD4230g Title: A Phase II/III, Randomized, Open-Label, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab

More information

How to Succeed in. Health and Life Sciences. Authors Mark Mozeson Elizabeth Shakhnovich

How to Succeed in. Health and Life Sciences. Authors Mark Mozeson Elizabeth Shakhnovich Health and Life Sciences point of view FEBRUARY 2013 How to Succeed in Autoimmune New Approaches for a Unique Disease Space Authors Mark Mozeson Elizabeth Shakhnovich Autoimmune diseases are an attractive

More information

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Report summary In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU

More information

Company Presentation

Company Presentation Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

Medicines for Rheumatoid. Arthritis. A Review of the Research for Adults

Medicines for Rheumatoid. Arthritis. A Review of the Research for Adults Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced

More information

Regulatory Status FDA-approved indication: Humira is a tumor necrosis factor (TNF) blocker indicated for the treatment of:

Regulatory Status FDA-approved indication: Humira is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.18.01 Subject: Humira Page: 1 of 8 Last Review Date: December 5, 2014 Humira Description Humira (adalimumab)

More information

H E A L T H C A R E. Key players, opportunities and future trends. Report Price Publication date. $3835 February 2010

H E A L T H C A R E. Key players, opportunities and future trends. Report Price Publication date. $3835 February 2010 F o r a c l e a r e r m a r k e t p e r s p e c t i v e The Specialty Pharmaceutical Market Outlook Key players, opportunities and future trends Report Price Publication date $3835 February 2010 H E A

More information

GLOBAL MARKETS FOR GENERIC DRUGS

GLOBAL MARKETS FOR GENERIC DRUGS GLOBAL MARKETS FOR GENERIC DRUGS PHM009H February 2017 Paul Evers Project Analyst ISBN: 1-62296-437-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the

More information

About The Report. Key Questions Answered in this Report:

About The Report. Key Questions Answered in this Report: About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients

More information

Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography ( )

Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography ( ) Brochure More information from http://www.researchandmarkets.com/reports/3784773/ Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2016-2021) Description:

More information

REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Astellas Irribow for Irritable Bowel Syndrome

More information

Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015

Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070278/ Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of

More information

Building on Leading Market Positions

Building on Leading Market Positions Building on Leading Market Positions Bharat Tewarie Head of Global Business Franchise Neurodegenerative Diseases Darmstadt, May 15, 2012 Agenda 1. Introduction 2. Rebif: Defending the franchise 3. Fertility:

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

Global Epilepsy Epidemiology and Patient Flow Analysis

Global Epilepsy Epidemiology and Patient Flow Analysis Brochure More information from http://www.researchandmarkets.com/reports/4030798/ Global Epilepsy Epidemiology and Patient Flow Analysis - 2017 Description: The results of the Epilepsy patients study are

More information

Global Haemophilia Epidemiology and Patient Flow Analysis - 2015

Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070298/ Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of its Haemophilia

More information

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion

MEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before

More information

Psoriatic Arthritis- Second Line Treatments

Psoriatic Arthritis- Second Line Treatments Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist

More information